Eptacog alfa

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Physical ActivityPostpartum

14 competitors in Physical Activity

#DrugCompanyPhaseTrials

1

Xolair

Roche

Approved

12

Hemlibra

Roche

Approved

—3

Ranexa

MMenarini International Operations Luxembourg SA

Approved

14

Eptacog alfa

Novo Nordisk

Phase 3

15

Taxol

Teva

Preclinical

16

Nicorette

Pfizer

Preclinical

17

Anamorelin Hydrochloride

MM.D. Anderson Cancer Center

Phase 2

18

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

19

Efanesoctocog Alfa

Sanofi

Preclinical

110

Immunotherapy

Bristol-Myers Squibb

Preclinical

—Show 2 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Haemophilia A6 trials

Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors

Completed·Novo Nordisk··NCT00703911·102 enrolled

Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice

Completed·Novo Nordisk··NCT01579955·321 enrolled

Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors

Completed·Novo Nordisk··NCT01586936·9 enrolled

Show 3 more trials

Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery

Completed·Novo Nordisk··NCT01579968·86 enrolled

Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography

Completed·Novo Nordisk·Phase 1·NCT01561924·17 enrolled

A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors

Completed·Novo Nordisk·Phase 1·NCT01949792·6 enrolled

Efficacy and Safety3 trials

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

Completed·Novo Nordisk·Phase 2·NCT03196284·26 enrolled

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

Completed·Bayer·Phase 2/3·NCT01625390·10 enrolled

Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors

Completed·Novo Nordisk·Phase 3·NCT01392547·72 enrolled

Treatment2 trials

Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern

Completed·Novo Nordisk··NCT04444856·225 enrolled

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

Completed·Novo Nordisk·Phase 1·NCT01561937·127 enrolled

Intracerebral Haemorrhage2 trials

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

Completed·Novo Nordisk·Phase 3·NCT00127283·829 enrolled

Factor VIIa in Acute Intracerebral Haemorrhage

Completed·Novo Nordisk·Phase 2·NCT00266006·90 enrolled

Prophylaxis1 trial

PROPACT: Retrospective Prophylaxis Patient Case Collection

Completed·Novo Nordisk··NCT00882778·86 enrolled

13 more indications

Hemophilia A1 trial

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

Terminated·CSL Behring·Phase 2/3·NCT02484638·25 enrolled

Asthenia1 trial

A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan

Completed·Novo Nordisk··NCT01876745·4 enrolled

Bleeding1 trial

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding

Terminated·Novo Nordisk·Phase 3·NCT00184548·554 enrolled

Trial1 trial

Trial of NovoSeven® in Haemophilia - Joint Bleeds

Completed·Novo Nordisk·Phase 4·NCT00108797·42 enrolled

Observational Study1 trial

Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany

Completed·Novo Nordisk··NCT00697320·64 enrolled

Physical Activity1 trial

A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors

Completed·Novo Nordisk··NCT01830712·15 enrolled

Efficacy1 trial

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

Terminated·Novo Nordisk·Phase 1·NCT01561950·91 enrolled

Spinal Surgery1 trial

Use of Activated Recombinant FVII in Spinal Surgery

Completed·Novo Nordisk·Phase 2·NCT00102037·50 enrolled

HAE1 trial

NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL

Completed·LLeiden University Medical Center··NCT04723979·3,322 enrolled

Hemophilia1 trial

Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors

Completed·AAryoGen Pharmed Co.·Phase 1·NCT04789954·14 enrolled

Acute1 trial

Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds

Completed·Novo Nordisk·Phase 2·NCT00486278·51 enrolled

Postpartum1 trial

Safety of Eptacog Alfa in Severe Postpartum Haemorrhage in India: A Phase IV Interventional Study

Recruiting·Novo Nordisk·Approved·NCT07157423·64 enrolled

Unspecified1 trial

Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects

Withdrawn·Novo Nordisk·Phase 1·NCT02084810

Details

Drug Info

Related News